Forward Pharma Is Selected As One of THE "2020 Guangdong-Hong Kong-Macao Greater Bay Area Innovation Power Enterprises"

On May 11th, the "2020 Guangdong-Hong Kong-Macao Greater Bay Area Enterprise Innovation Power List" was announced for the first time, and Shenzhen Forward Pharma Industry was selected as a "Future Creator Star" enterprise. 

The list covers 33 industries including biopharmaceuticals, medical devices, electronic information, new energy, new materials, and machinery. Overall, the selected companies attach great importance to independent innovation, have strong core competitiveness, focus on emerging industries, grow rapidly, and have outstanding industry status and strong market competitiveness. The purpose of the list is to give full play to Shenzhen's role as the center city of the Greater Bay Area, seize the major opportunities driven by the "Double Zone", and continuously enhance its core engine function in the construction of the Greater Bay Area. It promotes enterprises to vigorously implement innovation-driven development strategies, helps companies achieve the transformation of scientific and technological achievements into real productivity, fully stimulates enterprises' awareness of independent innovation, and builds a large stage for showcasing innovative achievements for enterprises in the Greater Bay Area.

Forward Pharma Industry's independently developed innovative targeted drug-FWD1509 for the treatment of EGFR exon20 insertion mutations in NSCLC has entered the international clinical trial stage in China and the United States. Currently, the Phase I clinical trial in the United States has officially started, and the clinical trial application in China is about to be approved and conducted simultaneously.

About Forward Pharma

Forward Pharma is an innovative pharmaceutical company that focuses on the independent research and development of drugs. It has a dual-platform approach that covers the entire drug development process, from target validation, drug discovery, early development, translational medicine research, preclinical studies, and clinical development. The company is headquartered in Nanshan, Shenzhen, with international operations and research teams in Shanghai and Shenzhen. Over the past seven years, relying on its self-built chemical small molecule and monoclonal antibody drug discovery platform, Forward Pharma has established a product matrix consisting of more than 10 Category 1 innovative drugs in over three major solid tumors and autoimmune diseases.